Fitzgerald Thomas A
Known title: Chief Financial OfficerCIK: 0001854168
Fitzgerald Thomas A's purchase track record
Fitzgerald Thomas A has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/28/2023 | RNAZ | $25K | -70.3% | -97.0% | +22.2% |
| 6/16/2022 | RNAZ | $15K | -7.9% | -64.3% | +6.2% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| RNAZ | ▲ Buy | Open Market | 49,350 | $25K | 9/28/2023 | View on chart |
| RNAZ | ▲ Buy | Open Market | 12,000 | $15K | 6/16/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
TransCode Reports Phase 1a Data for TTX-MC138
TransCode Therapeutics released updated results from its Phase 1a trial of TTX-MC138. The company reported continued disease stabilization and extended treatment duration in patients with advanced solid tumors. These findings add to the clinical evidence for the drug in heavily pretreated patients.
TransCode Reports Phase 1a Data for TTX-MC138. TransCode Therapeutics released updated results from its Phase 1a trial of TTX-MC138. The company reported continued disease stabilization and extended treatment duration in patients with advanced solid tumors. These findings add to the clinical evidence for the drug in heavily pretreated patients.